32,014 Shares in Cencora, Inc. (NYSE:COR) Acquired by AMF Tjanstepension AB

AMF Tjanstepension AB acquired a new position in shares of Cencora, Inc. (NYSE:COR) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 32,014 shares of the company’s stock, valued at approximately $7,782,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Vanguard Group Inc. bought a new position in Cencora in the fourth quarter valued at approximately $4,212,508,000. Wealth Enhancement Advisory Services LLC bought a new stake in shares of Cencora in the first quarter worth $66,911,000. PNC Financial Services Group Inc. bought a new stake in shares of Cencora in the fourth quarter worth $51,339,000. Los Angeles Capital Management LLC bought a new stake in shares of Cencora in the first quarter worth $45,692,000. Finally, Pensioenfonds Rail & OV acquired a new position in Cencora during the first quarter worth $37,371,000. Institutional investors own 97.52% of the company’s stock.

Cencora Trading Down 1.2 %

NYSE COR opened at $225.30 on Friday. The business’s fifty day moving average is $229.12 and its 200-day moving average is $227.82. Cencora, Inc. has a one year low of $171.65 and a one year high of $246.75. The stock has a market capitalization of $44.94 billion, a price-to-earnings ratio of 24.65, a PEG ratio of 1.58 and a beta of 0.48. The company has a debt-to-equity ratio of 3.41, a current ratio of 0.89 and a quick ratio of 0.53.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, May 1st. The company reported $3.80 earnings per share for the quarter, topping the consensus estimate of $3.65 by $0.15. Cencora had a return on equity of 268.67% and a net margin of 0.67%. The company had revenue of $68.41 billion during the quarter, compared to analyst estimates of $70.60 billion. During the same quarter last year, the firm posted $3.50 EPS. The firm’s revenue for the quarter was up 7.8% on a year-over-year basis. Equities research analysts predict that Cencora, Inc. will post 13.44 EPS for the current year.

Cencora Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, May 24th. Stockholders of record on Friday, May 10th were issued a dividend of $0.51 per share. This represents a $2.04 annualized dividend and a dividend yield of 0.91%. The ex-dividend date was Thursday, May 9th. Cencora’s payout ratio is 22.32%.

Analyst Upgrades and Downgrades

COR has been the topic of a number of recent analyst reports. StockNews.com downgraded shares of Cencora from a “strong-buy” rating to a “buy” rating in a report on Thursday, May 2nd. Robert W. Baird upped their price target on shares of Cencora from $275.00 to $277.00 and gave the company an “outperform” rating in a research note on Thursday, May 2nd. SVB Leerink restated an “outperform” rating and issued a $275.00 price target on shares of Cencora in a research note on Thursday. Finally, Citigroup upped their price target on shares of Cencora from $265.00 to $280.00 and gave the company a “buy” rating in a research note on Tuesday, April 30th. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $235.30.

Insider Transactions at Cencora

In related news, CEO Steven H. Collis sold 10,754 shares of the business’s stock in a transaction that occurred on Tuesday, April 16th. The stock was sold at an average price of $237.48, for a total value of $2,553,859.92. Following the completion of the sale, the chief executive officer now owns 285,088 shares in the company, valued at approximately $67,702,698.24. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other Cencora news, CEO Steven H. Collis sold 10,754 shares of the business’s stock in a transaction that occurred on Tuesday, April 16th. The stock was sold at an average price of $237.48, for a total value of $2,553,859.92. Following the completion of the sale, the chief executive officer now owns 285,088 shares in the company, valued at $67,702,698.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Robert P. Mauch sold 57,564 shares of the business’s stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $235.09, for a total value of $13,532,720.76. Following the transaction, the chief operating officer now directly owns 24,412 shares in the company, valued at $5,739,017.08. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 1,956,675 shares of company stock valued at $422,352,056. 15.80% of the stock is owned by corporate insiders.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.